PUBLISHER: The Business Research Company | PRODUCT CODE: 1810911
PUBLISHER: The Business Research Company | PRODUCT CODE: 1810911
Hereditary testing, also known as genetic testing for inherited conditions, involves analyzing an individual's DNA to detect genetic mutations or variations inherited from their parents. These tests help evaluate the risk of developing or passing on inherited diseases, assist in diagnosing genetic disorders, and support personalized treatment or preventive care decisions.
The primary types of hereditary testing include predictive testing, carrier testing, prenatal testing, newborn screening, diagnostic testing, and others. Predictive testing is used to determine the likelihood that an individual will develop a particular disease or condition in the future, before symptoms arise. Sample types for these tests include blood, saliva, tissue, buccal swabs, and urine. The technologies employed range from next-generation sequencing (NGS), polymerase chain reaction (PCR), Sanger sequencing, microarray technology, to whole genome sequencing (WGS). These tests are applied in various fields such as oncology, cardiovascular diseases, neurological disorders, metabolic disorders, and more, and are utilized by a wide range of end users including hospitals, diagnostic labs, research institutions, pharmaceutical companies, patients, and consumers.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.
The hereditary testing market research report is one of a series of new reports from The Business Research Company that provides hereditary testing market statistics, including hereditary testing industry global market size, regional shares, competitors with a hereditary testing market share, detailed hereditary testing market segments, market trends and opportunities, and any further data you may need to thrive in the hereditary testing industry. The hereditary testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The hereditary testing market size has grown strongly in recent years. It will grow from $6.05 billion in 2024 to $6.62 billion in 2025 at a compound annual growth rate (CAGR) of 9.3%. The growth during the historic period can be credited to increasing parental age, broader use in cancer risk assessment, heightened demand for early diagnosis and prevention, a rising burden of rare and chronic diseases, improved access to genetic counseling services, and greater adoption of hereditary testing in reproductive health.
The hereditary testing market size is expected to see strong growth in the next few years. It will grow to $9.35 billion in 2029 at a compound annual growth rate (CAGR) of 9.0%. The anticipated growth in the forecast period can be attributed to expanding collaborations between public and private genomic initiatives, rising demand for non-invasive prenatal testing (NIPT), an increasing variety of genetic testing panels and kits, greater use in population-wide screening programs, and a stronger focus on preventive and precision public health. Key trends during this period include advancements in next-generation sequencing (NGS), technological innovations in NIPT, progress in bioinformatics platforms, improvements in point-of-care genetic testing devices, and developments in multi-gene panel testing.
The rising prevalence of genetic disorders is expected to drive the growth of the hereditary testing market in the future. Genetic disorders are medical conditions caused by abnormalities or mutations in an individual's deoxyribonucleic acid (DNA), inherited from one or both parents or occurring spontaneously. The increase in genetic disorders is partly due to higher parental age, which raises the chances of passing genetic mutations to offspring. Hereditary testing aids patients with genetic disorders by enabling early diagnosis, guiding personalized treatments, and assisting family planning decisions through the identification of inherited mutations. For example, in October 2024, the Cystic Fibrosis Trust, a UK-based charity, reported that the number of registered cystic fibrosis patients increased to 11,318 in 2023, up from 11,148 in 2022. Thus, the growing prevalence of genetic disorders is fueling the hereditary testing market.
Key players in the hereditary testing market are focusing on technological advancements in genetic test kits to improve accuracy, shorten turnaround times, and expand the detection of a wider range of genetic mutations. Genetic test kits are diagnostic tools designed to analyze an individual's DNA to identify mutations or variations linked to inherited diseases or risk factors. For instance, in July 2023, Devyser Diagnostics AB, a Sweden-based biotech company specializing in DNA diagnostic kits for hereditary diseases, launched two new targeted next-generation sequencing kits: Devyser LynchFAP and Devyser BRCA PALB2. Devyser LynchFAP allows comprehensive analysis of PMS2 (addressing challenges from its pseudogene PMS2CL) along with nine other key genes associated with hereditary colorectal cancer syndromes. Devyser BRCA PALB2 provides a streamlined single-tube solution for screening BRCA1, BRCA2, and PALB2 mutations in both blood and tumor samples, designed to support efficient lab workflows with user-friendly sequencing and dedicated software for confident detection of hereditary cancer risks.
In May 2025, GeneDx LLC, a US-based biotechnology firm specializing in genetic testing, acquired Fabric Genomics for an undisclosed sum. This acquisition aims to enhance GeneDx's genomic interpretation capabilities by integrating Fabric Genomics' AI-powered platform, thereby strengthening its hereditary disease diagnostic offerings and enabling faster, more scalable genetic analysis. Fabric Genomics is a US-based computational genomics company providing hereditary testing solutions.
Major players in the hereditary testing market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Agilent Technologies Inc., Illumina Inc., CooperSurgical Inc., QIAGEN N.V, Natera Inc., Myriad Genetics Inc., Fulgent Genetics Inc, Invitae Corporation, GeneDx LLC, Twist Bioscience Corporation, Color Health Inc., MedGenome Inc, SOPHiA GENETICS SA, Gene By Gene Ltd., Dante Labs Inc., 23mofang Co. Ltd.
North America was the largest region in the hereditary testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in hereditary testing report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the hereditary testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The hereditary testing market includes revenues earned by entities through services such as genetic screening, pharmacogenetic testing, and presymptomatic testing. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Hereditary Testing Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on hereditary testing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for hereditary testing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The hereditary testing market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.